Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2021-02-25 10:10:33
Oslo, Norway, 25 February 2021
Reference is made to the stock exchange announcement on 23 February 2021
regarding the successful completion of Nordic Nanovector ASA's (OSE: NANOV) (the
"Company") private placement of new shares (the "Private Placement").
The share capital increase pertaining to the 15,878,122 new shares, each with a
nominal value of NOK 0.20, to be issued in the Private Placement (the "New
Shares") has been registered in the Norwegian Register of Business Enterprises
(the "NRBE") on 25 February 2021, and the Company's share capital has been
increased with NOK 3,175,624,40 through the issuance of the New Shares. The New
Shares are admitted to listing and made tradable on the Oslo Stock Exchange
following this stock exchange announcement.
Following registration of the share capital increase related to the New Shares
in the NRBE, the Company has an issued share capital of NOK 19,053,746.80,
divided into 95,268,734 shares, each with a par value of NOK 0.20. Each share
represents one vote in the Company's general meeting.
For further information, please contact:
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to the disclose requirements pursuant to Oslo Rule
Book II section 4.3.5.5 (4).